AXIM Moving Ahead with Testing of Cannabinoid Products, Including Chewing Gum for MS Patients
AXIM Biotechnologies announced it has secured financing from private sources to continue its testing of medical cannabinoid products as potential treatments for multiple indications, including pain and spasticity in people with multiple sclerosis (MS). Specifically, AXIM is testing pharmaceutical delivery systems and active ingredients for its medical marijuana line. “This financing provides us with…